Consistently, the combined treatment of JAK2 inhibitor ruxolitinib and venetoclax reduced leukemia burden in an IL7R mutant T-ALL mouse model in vivo [56]. This evidence concerns the gene IL7R and acute lymphoblastic leukemia.